알림

Novo Nordisk A/S (NONOF)

OTC Markets OTCPK: NONOF · 실시간 가격 · USD

44.78

-1.27 (-2.76%)

종가 기준: Aug 18, 2026, 9:30 AM

-2.76% (1D)

매수호가	44.5
시가총액	198.64B
매출 (ttm)	329.43B
순이익 (ttm)	116.44B
베타	0.35
EPS (ttm)	4.05
P/E (ttm)	11.09
선행 P/E	n/a
P/B (ttm)	5.83
P/S (ttm)	0.60
Earnings Date	Nov 4, 2026

매도호가	46.15
거래량	1,000
평균 거래량 (20일)	39,753
시가	44.78
전일 종가	46.05
일중 범위	44.78 - 44.78
52주 범위	34.00 - 64.75
애널리스트	n/a
목표주가	n/a
배당	$1.8 (4.01%)
배당락일	2026년 8월 14일

NONOF 소개

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products. It operates through two segments, Obesity and Diabetes Care, and Rare Disease. The Obesity and Diabetes care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine...

[더 보기]

산업 Drug Manufacturers - General

섹터 Healthcare

IPO 일자 Feb 22, 2010

직원 수 66,700

상장 거래소 OTC Markets OTCPK

티커 NONOF

웹사이트 https://www.novonordisk.com

전체 기업 정보

재무 실적

2025년 Novo Nordisk A/S의 매출은 309.06B로, 전년 290.4B 대비 6.43% 증가했습니다. 순이익은 102.43B로, 1.43% 증가했습니다.

재무제표

다음 실적 발표

Novo Nordisk A/S의 실적 발표 예정일은 Nov 4, 2026, 정규장 중입니다.
애널리스트 예상 매출은 ... 업그레이드

뉴스

18시간 전 · 24/7 Wall St.

Kailera Therapeutics: The Record-Breaking Obesity IPO Big Pharma Cannot Ignore

Kailera Therapeutics raised one of the biggest obesity biotech IPOs in recent memory, then watched its stock drop nearly 30%. Now several of the world's largest drugmakers have a compelling reason to ...

18시간 전 · Motley Fool

3 Absurdly Cheap Dividend Stocks to Buy for Under $100 Right Now

Novo Nordisk, CVS Health, and Bristol Myers are top dividend stocks that are trading at modest valuations.

1일 전 · Reuters Videos

Tech Weekly: soccer bots and balloon rockets

<body>STORY: From robots taking to the field, to an old-school way to orbit, this is Tech Weekly.:: Tech WeeklyCompetitors are limbering up for the second World Humanoid Robot Games i...

1일 전 · Zacks

LLY Up Around 6% Post Robust Q2 Results: Buy, Sell or Hold the Stock?

Lilly's strong Q2, GLP-1 momentum and broad pipeline support growth, but valuation and rising competition remain key risks.

1일 전 · Insider Monkey

Eli Lilly and Company (LLY)’s Weight-Loss Pill Just Won Its First Race in Europe. Novo Nordisk A/S (NVO) Still Has a Head Start

On August 10, Eli Lilly and Company (NYSE:LLY)’s weight-loss pill Foundayo won approval in the UK, becoming the first country in Europe to clear the drug for both weight management and type 2 diabetes...

2 페이지 중 1

Novo Nordisk A/S (NONOF)

NONOF 소개

재무 실적